» Articles » PMID: 28923897

Controlled Human Malaria Infection: Applications, Advances, and Challenges

Overview
Journal Infect Immun
Date 2017 Sep 20
PMID 28923897
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Controlled human malaria infection (CHMI) entails deliberate infection with malaria parasites either by mosquito bite or by direct injection of sporozoites or parasitized erythrocytes. When required, the resulting blood-stage infection is curtailed by the administration of antimalarial drugs. Inducing a malaria infection via inoculation with infected blood was first used as a treatment (malariotherapy) for neurosyphilis in Europe and the United States in the early 1900s. More recently, CHMI has been applied to the fields of malaria vaccine and drug development, where it is used to evaluate products in well-controlled early-phase proof-of-concept clinical studies, thus facilitating progression of only the most promising candidates for further evaluation in areas where malaria is endemic. Controlled infections have also been used to immunize against malaria infection. Historically, CHMI studies have been restricted by the need for access to insectaries housing infected mosquitoes or suitable malaria-infected individuals. Evaluation of vaccine and drug candidates has been constrained in these studies by the availability of a limited number of isolates. Recent advances have included cryopreservation of sporozoites, the manufacture of well-characterized and genetically distinct cultured malaria cell banks for blood-stage infection, and the availability of -specific reagents. These advances will help to accelerate malaria vaccine and drug development by making the reagents for CHMI more widely accessible and also enabling a more rigorous evaluation with multiple parasite strains and species. Here we discuss the different applications of CHMI, recent advances in the use of CHMI, and ongoing challenges for consideration.

Citing Articles

Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.

Kessy E, Olotu A Malar J. 2025; 24(1):33.

PMID: 39893367 PMC: 11786456. DOI: 10.1186/s12936-025-05277-x.


Ethics & utility of controlled human infection studies (CHIS) in low- & middle-income countries.

Eberts J, Eyal N, Banerjee S Indian J Med Res. 2024; 160(3&4):262-266.

PMID: 39632640 PMC: 11619065. DOI: 10.25259/IJMR_985_2024.


A human model of Buruli ulcer: Provisional protocol for a controlled human infection study.

Muhi S, Marshall J, OBrien D, Johnson P, Ross G, Ramakrishnan A Wellcome Open Res. 2024; 9:488.

PMID: 39386965 PMC: 11462124. DOI: 10.12688/wellcomeopenres.22719.1.


A feasibility study of controlled human infection with intradermal Bacillus Calmette-Guérin (BCG) injection: Pilot BCG controlled human infection model.

Carter E, Morton B, ElSafadi D, Jambo K, Kenny-Nyazika T, Hyder-Wright A Wellcome Open Res. 2024; 8:424.

PMID: 39219857 PMC: 11362739. DOI: 10.12688/wellcomeopenres.19811.2.


Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.

Wang L, Idris A, Kisalu N, Crompton P, Seder R Nat Immunol. 2024; 25(9):1530-1545.

PMID: 39198635 DOI: 10.1038/s41590-024-01938-2.


References
1.
Beadle C, Long G, Weiss W, McElroy P, Maret S, Oloo A . Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 1994; 343(8897):564-8. DOI: 10.1016/s0140-6736(94)91520-2. View

2.
Sedegah M, Peters B, Hollingdale M, Ganeshan H, Huang J, Farooq F . Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS One. 2016; 11(10):e0163026. PMC: 5047630. DOI: 10.1371/journal.pone.0163026. View

3.
Ockenhouse C, Hu W, Kester K, Cummings J, Stewart A, Heppner D . Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. Infect Immun. 2006; 74(10):5561-73. PMC: 1594921. DOI: 10.1128/IAI.00408-06. View

4.
de Mast Q, Groot E, Lenting P, de Groot P, McCall M, Sauerwein R . Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis. 2007; 196(4):622-8. DOI: 10.1086/519844. View

5.
Harpaz R, Edelman R, Wasserman S, Levine M, Davis J, Sztein M . Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. J Clin Invest. 1992; 90(2):515-23. PMC: 443129. DOI: 10.1172/JCI115889. View